Four out of 10 eczema patients struggle with sleep, and they may not volunteer that information unless you ask.

Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Regeneron Pharmaceuticals is conducting a clinical study ...

Regeneron’s shares have dropped sharply since peaking in August 2024, hurt by slowing Eylea sales due to competition from ...

Dupilumab may provide a nonsteroidal option for managing cancer therapy-related skin toxicities, according to a study.

At the same time, more than half of the US-listed stocks covered by Morningstar that reported earnings as of Aug. 11 beat ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Rothschild & Co Redburn initiated coverage of Regeneron (REGN) with a Buy rating and $890 price target Published first on TheFly – the ultimate ...

With multiple novel therapies expected and the treatment paradigm shifting toward earlier intervention, the market will grow ...

The SBB Research Group Foundation named Danielle Wang a recipient of its STEM scholarship. The $2,500 award empowers students ...

We closed out July 2025 in Boston alongside several of our Axinn colleagues attending the American Conference Institute’s ...

A patient has died from kidney injury in a trial of ’ lead antibody-drug conjugate, although the biotech has been advised to ...

In July 2025, Merck Sharp & Dohme LLC announced a substudy is to assess the efficacy and safety of ifinatamab deruxtecan ...